Samsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Pre-filled Syringe Across Europe
Samsung Bioepis Co., Ltd. today announced the launch of OPUVIZ™ 40 mg/mL solution in pre-filled syringe (PFS), a biosimilar referencing Eylea1(aflibercept), across Europe, starting today.“We are pleased to introduce the pre-filled syringe presentation of OPUVIZ to the European market, building on th
Samsung Bioepis has launched OPUVIZ™, a 40 mg/mL pre-filled syringe (PFS) of the biosimilar aflibercept, throughout Europe. The company's Vice President and Head of Europe, Antonio Rito, expressed satisfaction with the introduction of this new format, highlighting its convenience for injections and improved dosing precision compared to the vial version.
OPUVIZ PFS aims to provide ophthalmologists with an additional option for managing retinal diseases effectively. The company has been offering OPUVIZ 40 mg/mL solution for injection in vials since May this year, and the product is also available in South Korea under the brand name AFILIVU™. Aflibercept, a vascular endothelial growth factor (VEGF) inhibitor, works by blocking abnormal blood vessel growth and leakage in the eye.
OPUVIZ was first approved for treating various eye conditions, including wet age-related macular degeneration, macular oedema, diabetic macular oedema, and myopic choroidal neovascularisation, by the European Commission in November 2024 and the Medicines and Healthcare products Regulatory Agency in April 2025.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
